Working to Eradicate Gynecologic Cancers

53
A phase II trial of trebaninib (AMG 386), a selective angiopoietin 1/2 neuralizing peptibody in patients with persistent/recurrent carcinoma of the endometrium: a Gynecologic Oncology Group study

Tuesday, March 31, 2015: 8:27 AM
International Ballroom (Hilton Chicago)
K. N. Moore1, M. Sill2, M. E. Tenney3, C. J. Darus4, D. Griffin5, T. L. Werner6, S. E. Waggoner7 and R. J. Behrens8
1The University of Oklahoma, Oklahoma City, OK, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3University of Chicago, Chicago, IL, 4Maine Medical Partners, Scarborough, ME, 5Anmed Gynecologic Oncology/Upstate Oncology Associates, Anderson, SC, 6University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, 7University Hospitals Case Medical Center, Cleveland, OH, 8Iowa Oncology Research Association, Des Moines, IA
 
 
See more of: Scientific Plenary VIII
See more of: Scientific Plenary
<< Previous Presentation | Next Presentation >>